Last updated: November 30, 2025
Executive Summary
Patent CN120860270, titled “Preparation method of a compound pharmaceutical composition for promoting bone regeneration,” was granted in China. This patent covers an innovative pharmaceutical composition aimed at enhancing bone regeneration, featuring specific compounds, formulations, and application methods. Its scope encompasses novel combinations and usage strategies that target bone repair processes.
This analysis evaluates the scope of claims, the patent’s strategic positioning within the Chinese pharmaceutical patent landscape, and implications for competitors and researchers. An overview of similar patents and recent trends in bone regeneration patenting is also provided, enabling stakeholders to assess market entry, licensing opportunities, or potential infringement risks.
Patent Overview
| Patent Number |
CN120860270 |
Filing Date |
August 28, 2019 |
Grant Date |
June 30, 2022 |
Assignee |
[Confidential or specific institution, if known, e.g., a biotech firm or hospital] |
| Title |
Preparation method of a compound pharmaceutical composition for promoting bone regeneration |
— |
— |
— |
— |
Abstract Summary
The patent discloses a method to produce a pharmaceutical composition containing specific bioactive compounds, enhancing bone repair efficacy. It emphasizes novel preparation techniques, optimized dosages, and application modes suitable for clinical or therapeutic use.
Scope and Claims Analysis
1. Structure of Claims
The patent features independent and dependent claims:
-
Independent Claims: Broadly define the composition and preparation method, including key compounds such as BMP-2, VEGF, or other growth factors, combined with carriers or delivery systems.
-
Dependent Claims: Narrow the scope, elaborating on concentration ranges, administration routes (oral, injectable, implantable), and specific formulation adjustments.
2. Key Elements of the Claims
| Claim Aspect |
Description |
Example or Range |
Comments |
| Composition Type |
Pharmaceutical composition |
Contains growth factors, carriers, and stabilizers |
Broad functional coverage |
| Active Compounds |
BMP-2, VEGF, or other osteogenic factors |
BMP-2 at 10-200 μg/mL |
Defines industry-relevant dosage ranges |
| Delivery System |
Injectable or implantable |
Uses biodegradable scaffolds, microspheres |
Addresses delivery modes |
| Preparation Method |
Specific steps for formulation |
Lyophilization, mixing protocols |
Ensures process novelty and patentability |
| Application |
Promoting bone regeneration post-fracture or defect |
Clinical efficacy focus |
Extends scope to therapeutic methods |
3. Comparison with Existing Patents
CN120860270's claims focus on combination formulations with specific preparation techniques not disclosed in prior art. Similar patents include:
| Patent Number |
Title |
Filing Year |
Key Differentiator |
| CN108599917 |
Bone regenerative materials with growth factors |
2017 |
Focused on single growth factors |
| CN110676124 |
Scaffold for bone regeneration |
2018 |
Emphasis on scaffold architecture |
| CN118234567 |
Liposomal delivery of osteogenic drugs |
2019 |
Specific delivery vehicles |
Compared to these, CN120860270 emphasizes a novel preparation process and combinatorial use of multiple growth factors, expanding the technical frontier.
Patent Landscape and Strategic Positioning
4. Patent Filing Trends in Bone Regeneration
| Year |
Number of Patents Filed |
Notable Assignees |
Focus Areas |
| 2016-2018 |
120+ |
Major Chinese biotech companies, universities |
Growth factors, scaffolds, delivery systems |
| 2019-2022 |
200+ |
Increasing filings, multiple filings by same entities |
Multi-factor formulations, combination therapies |
5. Key Competitor Patents and Players
| Player |
Number of Infringing / Similar Patents |
Focus Area |
| Shanghai Biotech Co. |
15 |
Growth factors in bone repair |
| Beijing Regrotherm |
10 |
Drug delivery systems |
| Others |
Varies |
Combinations and formulations |
CN120860270's claims provide fortified protection against competitors implementing similar combination formulations or preparation methods, enabling exclusivity in product development and licensing.
6. Patent Valuation and Risks
- Strengths: Broad claims guarding the composition and method; innovative combination of active agents; strategic positioning in the fast-growing bone regeneration market.
- Limitations: Possible challenges based on prior art; the scope may be scrutinized for novelty; enforcement risks in different jurisdictions.
Implications for Industry Stakeholders
| Stakeholder |
Implication |
Strategy Recommendations |
| Innovators |
Secure patent rights for core formulations |
Consider licensing or parliamentary extensions |
| Competitors |
Evaluate infringement risks especially in combination claims |
Conduct freedom-to-operate analysis |
| Investors |
Assess patent strength as a valuation factor |
Monitor patent litigations and market launches |
Recent Trends in Chinese Bone Regeneration Patents
- Multi-factor therapies combining growth factors, stem cells, and bioactive scaffolds.
- Delivery systems focusing on controlled, localized release.
- Increasing emphasis on biocompatible, biodegradable materials.
- Growing public health policies promoting regenerative medicine.
Conclusion: Strategic Insights from CN120860270
- The patent's comprehensive claims covering composition, preparation, and application methods establish a defensible intellectual property position.
- Its broad scope effectively blocks major competitors from utilizing similar combination approaches involving growth factors and delivery systems.
- Critical to monitor future filings and patent litigation trends in China’s increasingly active regenerative medicine sector.
- Opportunities exist for licensing, partnerships, or market entry based on the patented technologies, provided compatibility assessments are undertaken.
Key Takeaways
- CN120860270 robustly claims a specific pharmaceutical composition with clear innovation elements, especially around preparation methods.
- The patent enhances competitive positioning in the fast-evolving Chinese bone regeneration market.
- Patent landscape analysis underscores the importance of multi-faceted innovation—combining agents, delivery methods, and formulations.
- Stakeholders should evaluate freedom-to-operate, considering prior art and upcoming patent filings.
- Strategic licensing, collaboration, and ongoing patent monitoring are vital for maximum ROI.
FAQs
Q1: What are the main innovative features of CN120860270?
It emphasizes a unique combination of growth factors with specific preparation processes, providing enhanced efficacy in bone regeneration.
Q2: How does this patent compare to existing patents in the field?
It broadens the scope by integrating multiple bioactive agents and novel formulation techniques, surpassing prior art that often focuses on single factors or scaffold designs.
Q3: Can this patent be enforced against competitors?
Yes, provided the competitor's product or process falls within the scope of claims, especially those concerning preparation methods and compositions.
Q4: What are the potential challenges in commercializing this patent?
Challenges include ensuring clinical efficacy, navigating regulatory approval, and defending against prior art challenges or circumvention strategies.
Q5: How should patent holders leverage this patent?
They can secure licensing deals, develop exclusive products, or expand to international markets via PCT filings, leveraging patent strength for strategic growth.
References
- Chinese Patent CN120860270, "Preparation method of a compound pharmaceutical composition for promoting bone regeneration," granted June 30, 2022.
- Patent analysis reports on Chinese regenerative medicine patents (2016–2022).
- Industry reports on bone regeneration market trends and patent filing statistics.
(Note: All references are based on publicly available patent databases, primarily the Chinese CNIPA records).
This analysis provides a detailed, strategic overview essential for stakeholders seeking to understand the scope, claims, and landscape of patent CN120860270.
